ArticleFrontiers in neurology2025
Metabolomic analysis reveals trimethylamine N-oxide as a biomarker for poor outcome of severe spontaneous intracerebral hemorrhage patients receiving surgical treatment.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Patients suffering from severe spontaneous intracerebral hemorrhage (SSICH) are at high risk of cardiocerebrovascular diseases postoperatively, which hugely affect patients' long-term outcomes. Metabolic features could reflect the pathological change of the cardiocerebrovascular system and might serve as biomarkers for evaluating the risk of poor outcomes in SSICH patients. The current study aimed to find the early-warning biomarkers for poor outcomes in SSICH patients after surgery. Methods: Severe spontaneous intracerebral hemorrhage patients receiving surgical treatment from a referring hospital were prospectively included and formed the primary cohort after propensity score matching. The primary outcome is poor 180 days after hemorrhage (modified Rankin scale ≥4). Metabolomics analysis on 3-, 7-, and 30-day serum and cerebrospinal fluid samples after surgery revealed the dysregulated metabolites of SSICH patients within the primary cohort. Within the validation cohort of SSICH patients receiving surgical treatment from a multicenter, prospective cohort, dysregulated metabolites were validated and evaluated to see whether they could serve as biomarkers for 180-day poor outcomes by area under the curve (AUC). Results: The primary cohort included 20 SSICH patients with good 180-day outcome and 20 with poor outcome. Untargeted metabolomics analysis found 25 co-dysregulated metabolites, including trimethylamine N-oxide (TMAO), among 3-day, 7-day, and 30-day metabolism features between SSICH patients with poor outcome and good outcome after surgery. A good correlation was found in TMAO between serum and cerebrospinal fluid on 3rd day after surgery. Based on the validation cohort of 794 SSICH patients (147 patients had 180-day poor outcome), the targeted metabolomics analysis revealed increasing TMAO on 3rd day after surgery as a risk factor of poor outcomes (odds ratio, 4.7; 95%CI, 3.6-6.2; Conclusion: This study demonstrated increasing serum TMAO level as an early-warning biomarker for 180-day poor outcomes of SSICH patients receiving surgical treatment. Clinical trial registration: Chinese Clinical Trial Registry, ChiCTR1900024406, https://www.chictr.org.cn/showproj.html?proj=40640.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.